Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors

Pazopanib is US FDA approved for the treatment of advanced soft tissue sarcomas. All patients with this disease ultimately develop resistance to therapy. Mechanisms of resistance include activation of the mTOR, histone deacetylase (HDAC), MAPK, and ERBB4 pathways. We hypothesized that combining pazo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dembla, Vikas, Groisberg, Roman, Hess, Ken, Fu, Siqing, Wheler, Jennifer, Hong, David S., Janku, Filip, Zinner, Ralph, Piha-Paul, Sarina Anne, Ravi, Vinod, Benjamin, Robert S., Patel, Shreyaskumar, Somaiah, Neeta, Herzog, Cynthia E., Karp, Daniel D., Roszik, Jason, Meric-Bernstam, Funda, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698336/
https://www.ncbi.nlm.nih.gov/pubmed/29162825
http://dx.doi.org/10.1038/s41598-017-13114-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698336/
https://www.ncbi.nlm.nih.gov/pubmed/29162825
http://dx.doi.org/10.1038/s41598-017-13114-8

Ejemplares similares